Suttorp M, Sembill S, Metzler M (2020)
Publication Type: Journal article
Publication year: 2020
DOI: 10.1055/a-1248-2294
Background CML comprises only 2-3 % of all diagnosed pediatric leukemias. Mostly diagnosed in chronic phase (CML-CP), the disease progresses without treatment to accelerated phase (CML-AP) and finally to life-limiting blastic phase (CML-BP). Contrasting the therapy of other leukemia types, CML-CP is not treated by intense chemotherapy but with oral drugs - termed tyrosine kinase inhibitors (TKI)- for an unlimited duration. This therapy may be associated with general and developmental-specific side effects. The rarity of pediatric-CML is limiting the experience in assessment of the disability rating (DR) as an administrative health authority procedure.
APA:
Suttorp, M., Sembill, S., & Metzler, M. (2020). Disability Rating in Children and Adolescents with Chronic Myeloid Leukemia. Klinische Pädiatrie. https://doi.org/10.1055/a-1248-2294
MLA:
Suttorp, Meinolf, Stephanie Sembill, and Markus Metzler. "Disability Rating in Children and Adolescents with Chronic Myeloid Leukemia." Klinische Pädiatrie (2020).
BibTeX: Download